Coda Biotherapeutics appoints Michael Narachi to its Board as CEO along with raising $19m Series A financing led by MPM Capital and Versant Ventures
– USA, CA – CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform for the treatment of intractable diseases, today debuted with a $19 million Series A financing.…